Search

Your search keyword '"Yahav, Dafna"' showing total 909 results
Start Over Author "Yahav, Dafna" Publication Year Range Last 50 years
909 results on '"Yahav, Dafna"'

2. Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases.

Author

Aslam, Saima, Roach, Dwayne, Nikolich, Mikeljon P, Biswas, Biswajit, Schooley, Robert T, Lilly-Bishop, Kimberley A, Rice, Gregory K, Cer, Regina Z, Hamilton, Theron, Henry, Matthew, Luong, Tiffany, Salabarria, Ann-Charlott, Sisk-Hackworth, Laura, Filippov, Andrey A, Lebreton, Francois, Hall, Lindsey, Nir-Paz, Ran, Onallah, Hadil, Livni, Gilat, Shostak, Eran, Wieder-Finesod, Anat, Yahav, Dafna, Yerushalmy, Ortal, Alkalay-Oren, Sivan, Braunstein, Ron, Khalifa, Leron, Rimon, Amit, Gelman, Daniel, and Hazan, Ronen

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Biodefense, Assistive Technology, Antimicrobial Resistance, Infectious Diseases, Prevention, Cardiovascular, Rare Diseases, Heart Disease, Vaccine Related, Bioengineering, Emerging Infectious Diseases, Infection, LVAD, MDRO, Pseudomonas aeruginosa, device-related infection, phage therapy, Microbiology, Pharmacology and Pharmaceutical Sciences, Medical microbiology, Pharmacology and pharmaceutical sciences
Abstract

Left ventricular assist devices (LVAD) are increasingly used for management of heart failure; infection remains a frequent complication. Phage therapy has been successful in a variety of antibiotic refractory infections and is of interest in treating LVAD infections. We performed a retrospective review of four patients that underwent five separate courses of intravenous (IV) phage therapy with concomitant antibiotic for treatment of endovascular Pseudomonas aeruginosa LVAD infection. We assessed phage susceptibility, bacterial strain sequencing, serum neutralization, biofilm activity, and shelf-life of phage preparations. Five treatments of one to four wild-type virulent phage(s) were administered for 14-51 days after informed consent and regulatory approval. There was no successful outcome. Breakthrough bacteremia occurred in four of five treatments. Two patients died from the underlying infection. We noted a variable decline in phage susceptibility following three of five treatments, four of four tested developed serum neutralization, and prophage presence was confirmed in isolates of two tested patients. Two phage preparations showed an initial titer drop. Phage biofilm activity was confirmed in two. Phage susceptibility alone was not predictive of clinical efficacy in P. aeruginosa endovascular LVAD infection. IV phage was associated with serum neutralization in most cases though lack of clinical effect may be multifactorial including presence of multiple bacterial isolates with varying phage susceptibility, presence of prophages, decline in phage titers, and possible lack of biofilm activity. Breakthrough bacteremia occurred frequently (while the organism remained susceptible to administered phage) and is an important safety consideration.

Published
2024

6. The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe.

Author

Tong, Steven, Mora, Jocelyn, Bowen, Asha, Cheng, Matthew, Daneman, Nick, Goodman, Anna, Heriot, George, Lee, Todd, Lewis, Roger, Lye, David, Mahar, Robert, Marsh, Julie, McGlothlin, Anna, McQuilten, Zoe, Morpeth, Susan, Paterson, David, Price, David, Roberts, Jason, Robinson, J, van Hal, Sebastiaan, Walls, Genevieve, Webb, Steve, Whiteway, Lyn, Yahav, Dafna, and Davis, Joshua

Subjects
Staphylococcus aureus, adaptive platform, bacteremia, bloodstream infection, randomized controlled trial, Humans, Anti-Bacterial Agents, Bacteremia, Staphylococcal Infections, Staphylococcus aureus
Abstract

Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%-30%. Despite this,

Published
2022

8. Outcomes of octogenarians and nonagenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study

Author

Atamna, Alaa, Margalit, Ili, Ayada, Gida, Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Ruben, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, de Cueto, Marina, Oliver, Antonio, de Gopegui, Enrique Ruiz, Cano, Angela, Machuca, Isabel, Gozalo-Marguello, Monica, Martinez-Martinez, Luis, Gonzalez-Barbera, Eva M., Alfaro, Iris Gomez, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller–Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstei, Yaakov, and Yahav, Dafna

Published
2023
Full Text
View/download PDF

10. Nationwide Outbreak of Candida auris Infections Driven by COVID-19 Hospitalizations, Israel, 2021-2022

Author

Biran, Roni, Cohen, Regev, Finn, Talya, Brosh-Nissimov, Tal, Rahav, Galia, Yahav, Dafna, Amit, Sharon, Shachor-Meyouhas, Yael, Atamna, Alaa, Bishara, Jihad, Ashkenazi-Hoffnung, Liat, Zvi, Haim Ben, Hershman-Sarafov, Mirit, Maayan, Shlomo, Maor, Yasmin, Schwartz, Orna, Zimhony, Oren, Lellouche, Jonathan, Elbaz, Meital, Burdelova, Ela, Mizrahi, Naama, Novikov, Anna, Henig, Oryan, and Ben-Ami, Ronen

Subjects
Epidemics -- Statistics -- Risk factors -- Israel, Hospital care -- Statistics, Candidiasis -- Statistics -- Risk factors, Health
Abstract

Candida auris is a drug-resistant fungal pathogen that has emerged over the past decade as a cause of nosocomial outbreaks with substantial mortality rates (1-3). Widespread resistance to triazole antifungals, [...]

Published
2023
Full Text
View/download PDF

13. Universal Risk Factors for Mortality in Bloodstream Infections (UNIFORM): a systematic review and Delphi survey

Author

Bonten, Marc, Carmeli, Yehuda, Carrara, Elena, Chambers, Henry F., Davis, Joshua S., Daikos, George L., de Kraker, Marlieke, Durante-Mangoni, Emanuele, Huttner, Angela, Kalil, Andre C., Kaye, Keith, Lee, Todd C., Leibovici, Leonard, Palacios-Baena, Zaira R., Paterson, David, Paul, Mical, Gentil, Pilar Retamar, Baño, Jesus Rodríiguez, Scudeller, Luigia, Tacconelli, Evelina, Thwaites, Guy, Tong, Steven, Varon, Ben, Yahav, Dafna, de Kraker, Marlieke E.A., and Rodríguez-Baño, Jesús

Published
2024
Full Text
View/download PDF

17. Refractory Pseudomonas aeruginosa infections treated with phage PASA16: A compassionate use case series

Author

Onallah, Hadil, Hazan, Ronen, Nir-Paz, Ran, Brownstein, Michael J., Fackler, Joseph R., Horne, Bri’Anna, Hopkins, Robert, Basu, Subhendu, Yerushalmy, Ortal, Alkalay-Oren, Sivan, Braunstein, Ron, Rimon, Amit, Gelman, Daniel, Khalifa, Leron, Adler, Karen, Abdalrhman, Mohanad, Gelman, Shira, Katvan, Eyal, Coppenhagen-Glazer, Shunit, Moses, Allon, Oster, Yonatan, Dekel, Michal, Ben-Ami, Ronen, Khoury, Amal, Kedar, Daniel J., Meijer, Suzy E., Ashkenazi, Itay, Bishouty, Nancy, Yahav, Dafna, Shostak, Eran, Livni, Gilat, Paul, Mical, Gross, Menachem, Ormianer, Matityahou, Aslam, Saima, Ritter, Michele, Urish, Kenneth L., La Hoz, Ricardo M., Khatami, Ameneh, Britton, Philip N., Lin, Ruby C.Y., Iredell, Jonathan R., Petrovic-Fabijan, Aleksandra, Lynch, Stephanie, Tamma, Pranita D., Yamshchikov, Alexandra, Lesho, Emil, Morales, Megan, Werzen, Alissa, and Saharia, Kapil

Published
2023
Full Text
View/download PDF

19. Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study

Author

Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Ruben, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, de Cueto, Marina, Oliver, Antonio, de Gopegui, Enrique Ruiz, Cano, Angela, Machuca, Isabel, Gozalo-Marguello, Monica, Martinez-Martinez, Luis, Gonzalez-Barbera, Eva M., Alfaro, Iris Gomez, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller–Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, and Yahav, Dafna

Published
2022
Full Text
View/download PDF

21. Varicella zoster virus-induced neurological disease after COVID-19 Vaccination: A Multicenter Observational Cohort Study

Author

Elbaz, Meital, primary, Hoffman, Tomer, additional, Yahav, Dafna, additional, Dovrat, Sarah, additional, Ghanem-Zoubi, Nesrin, additional, Atamna, Alaa, additional, Grupel, Daniel, additional, Reisfeld, Sharon, additional, Hershman-Sarafov, Mirit, additional, Ciobotaro, Pnina, additional, Najjar-Debbiny, Ronza, additional, Brosh-Nissimov, Tal, additional, Chazan, Bibiana, additional, Yossepowitch, Orit, additional, Wiener-Well, Yonit, additional, Halutz, Ora, additional, Reich, Shelley, additional, Ben-Ami, Ronen, additional, and Paran, Yael, additional

Published
2024
Full Text
View/download PDF

22. Characteristics of long-COVID among older adults: a cross-sectional study

Author

Daitch, Vered, Yelin, Dana, Awwad, Muhammad, Guaraldi, Giovanni, Milić, Jovana, Mussini, Cristina, Falcone, Marco, Tiseo, Giusy, Carrozzi, Laura, Pistelli, Francesco, Nehme, Mayssam, Guessous, Idris, Kaiser, Laurent, Vetter, Pauline, Bordas-Martínez, Jaume, Durà-Miralles, Xavier, Peleato-Catalan, Dolores, Gudiol, Carlota, Shapira-Lichter, Irit, Abecasis, Donna, Leibovici, Leonard, Yahav, Dafna, and Margalit, Ili

Published
2022
Full Text
View/download PDF

23. Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.

Author

Doernberg, Sarah B, Tran, Thuy Tien Tram, Tong, Steven YC, Paul, Mical, Yahav, Dafna, Davis, Joshua S, Leibovici, Leonard, Boucher, Helen W, Corey, G Ralph, Cosgrove, Sara E, Chambers, Henry F, Fowler, Vance G, Evans, Scott R, and Holland, Thomas L

Subjects
Clinical Trials and Supportive Activities, Emerging Infectious Diseases, Infectious Diseases, Clinical Research, Infection, Good Health and Well Being, Adult, Anti-Bacterial Agents, Bacteremia, Humans, Methicillin-Resistant Staphylococcus aureus, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Risk Factors, Staphylococcal Infections, Staphylococcus aureus, Surveys and Questionnaires, Survival Analysis, clinical trial, bloodstream infection, Antibacterial Resistance Leadership Group, Staphylococcus aureus, Biological Sciences, Medical and Health Sciences, Microbiology
Abstract

BackgroundDesirability of outcome ranking (DOOR) is an innovative approach in clinical trials to evaluate the global benefits and risks of an intervention. We developed and validated a DOOR endpoint for Staphylococcus aureus bloodstream infection (BSI) through a survey to infectious diseases clinicians and secondary analysis of trial data.MethodsWe administered a survey of 20 cases of S. aureus BSI, asking respondents to rank outcomes by global desirability. Correlations and percentage of pairwise agreement among rankings were estimated to inform development of a DOOR endpoint, which was applied to 2 prior S. aureus BSI trials. The probability that a patient randomly assigned to experimental treatment would have a better DOOR ranking than if assigned to control was estimated. Results were also analyzed using partial credit, which is analogous to scoring an academic test, assigning 100% to the most desirable outcome, 0% to the least, and "partial credit" to intermediate ranks.ResultsForty-two recipients (97%) completed the survey. The DOOR endpoint fitting these rankings (r = 0.89; 95% confidence interval, 0.67 to 0.94) incorporated survival plus cumulative occurrence of adverse events, cure, infectious complications, and ongoing symptoms. Tailored versions of this endpoint were applied to 2 S. aureus BSI trials, and both demonstrated no benefit of the experimental treatment using DOOR and partial credit analysis.ConclusionsUsing S. aureus BSI as an exemplar, we developed a DOOR endpoint that can be used as a template for development of DOOR endpoints for other diseases. Future trials can incorporate DOOR to allow for global assessment of patient experience.

Published
2019

30. Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol.

Author

Kretser, Dana de, Mora, Jocelyn, Bloomfield, Max, Campbell, Anita, Cheng, Matthew P, Guy, Stephen, Hensgens, Marjolein, Kalimuddin, Shirin, Lee, Todd C, Legg, Amy, Mahar, Robert K, Marks, Michael, Marsh, Julie, McGlothin, Anna, Morpeth, Susan C, Sud, Archana, Oever, Jaap Ten, Yahav, Dafna, Bonten, Marc, and Bowen, Asha C

Subjects
ANTIBIOTICS, BACTEREMIA, ORAL drug administration, STAPHYLOCOCCUS aureus, RANDOMIZED controlled trials, INTRAVENOUS therapy
Abstract

Background Staphylococcus aureus bloodstream infection (bacteremia) is traditionally treated with at least 2 weeks of intravenous (IV) antibiotics in adults, 3–7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia (SAB) with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients. Protocol The early oral switch (EOS) domain of the S. aureus Network Adaptive Platform (SNAP) trial will assess early switch to oral antibiotics compared with continued IV treatment in clinically stable patients with SAB. The primary endpoint is 90-day all-cause mortality. Hospitalised SAB patients are assessed at platform day 7 ±2 (uncomplicated SAB) and day 14 ±2 (complicated SAB) to determine their eligibility for randomization to EOS (intervention) or continued IV treatment (current standard of care). Discussion Recruitment is occurring in the EOS domain of the SNAP trial. As of August 2023, 21% of all SNAP participants had been randomized to the EOS domain, a total of 264 participants across 77 centers, with an aim to recruit at least 1000 participants. We describe challenges and facilitators to enrolment in this domain to aid those planning similar trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. In vivo fitness of carbapenem-resistant Acinetobacter baumannii strains in murine infection is associated with treatment failure in human infections

Author

Paul, Mical, Benattar, Yael Dishon, Dickstein, Yaakov, Bitterman, Roni, Zayyad, Hiba, Koppel, Fidi, Zak-Doron, Yael, Altunin, Sergey, Andria, Nizar, Neuberger, Ami, Stern, Anat, Petersiel, Neta, Raines, Marina, Karban, Amir, Leibovici, Leonard, Yahav, Dafna, Eliakim-Raz, Noa, Zusman, Oren, Elbaz, Michal, Atamna, Heyam, Daitch, Vered, Babich, Tanya, Carmeli, Yehuda, Nutman, Amir, Adler, Amos, Levi, Inbar, Daikos, George L., Skiada, Anna, Pavleas, Ioannis, Antoniadou, Anastasia, Kotsaki, Antigoni, Durante-Mangoni, Emanuele, Andini, Roberto, Iossa, Domenico, Bernardo, Mariano, Cavezza, Giusi, Bertolino, Lorenzo, Giuffre, Giuseppe, Giurazza, Roberto, Ruocco, Giuseppe, Galdo, Maria, Murino, Patrizia, Cristinziano, Adriano, Corcione, Antonio, Zampino, Rosa, Mouton, Johan, Friberg, Lena, Theuretzbacher, Ursula, Temkin, Elizabeth, Lellouche, Jonathan, Rakovitsky, Nadya, Hameir, Amichay, Daikos, George, Dishon, Yael, Eliakim, Noa, and Friberg, Lena E.

Published
2022
Full Text
View/download PDF

35. Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases

Author

Aslam, Saima, primary, Roach, Dwayne, additional, Nikolich, Mikeljon P., additional, Biswas, Biswajit, additional, Schooley, Robert T., additional, Lilly-Bishop, Kimberley A., additional, Rice, Gregory K., additional, Cer, Regina Z., additional, Hamilton, Theron, additional, Henry, Matthew, additional, Luong, Tiffany, additional, Salabarria, Ann-Charlott, additional, Sisk-Hackworth, Laura, additional, Filippov, Andrey A., additional, Lebreton, Francois, additional, Hall, Lindsey, additional, Nir-Paz, Ran, additional, Onallah, Hadil, additional, Livni, Gilat, additional, Shostak, Eran, additional, Wieder-Finesod, Anat, additional, Yahav, Dafna, additional, Yerushalmy, Ortal, additional, Alkalay-Oren, Sivan, additional, Braunstein, Ron, additional, Khalifa, Leron, additional, Rimon, Amit, additional, Gelman, Daniel, additional, and Hazan, Ronen, additional

Published
2024
Full Text
View/download PDF

45. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes

Author

Paul, Mical, Benattar, Yael Dishon, Dickstein, Yaakov, Bitterman, Roni, Zayyad, Hiba, Koppel, Fidi, Zak-Doron, Yael, Altunin, Sergey, Andria, Nizar, Neuberger, Ami, Stern, Anat, Petersiel, Neta, Raines, Marina, Karban, Amir, Leibovici, Leonard, Yahav, Dafna, Eliakim-Raz, Noa, Zusman, Oren, Elbaz, Michal, Atamna, Heyam, Daitch, Vered, Babich, Tanya, Carmeli, Yehuda, Nutman, Amir, Adler, Amos, Levi, Inbar, Daikos, George L., Skiada, Anna, Pavleas, Ioannis, Antoniadou, Anastasia, Kotsaki, Antigoni, Durante-Mangoni, Emanuele, Andini, Roberto, Iossa, Domenico, Bernardo, Mariano, Cavezza, Giusi, Bertolino, Lorenzo, Giuffre, Giuseppe, Giurazza, Roberto, Cuccurullo, Susanna, Galdo, Maria, Murino, Patrizia, Cristinziano, Adriano, Corcione, Antonio, Zampino, Rosa, Pafundi, Pia Clara, Mouton, Johan, Friberg, Lena, Kristoffersson, Anders, Theuretzbacher, Ursula, Lellouche, Jonathan, Temkin, Elizabeth, Daikos, George, Dishon-Benattar, Yael, Friberg, Lena E., and Mouton, Johan W.

Published
2020
Full Text
View/download PDF

48. Universal Risk Factors for Mortality in Bloodstream Infections (UNIFORM): a systematic review and Delphi survey

Author

Varon, Ben, primary, Palacios-Baena, Zaira R., additional, de Kraker, Marlieke E.A., additional, Rodríguez-Baño, Jesús, additional, Leibovici, Leonard, additional, Paul, Mical, additional, Bonten, Marc, additional, Carmeli, Yehuda, additional, Carrara, Elena, additional, Chambers, Henry F., additional, Davis, Joshua S., additional, Daikos, George L., additional, Kraker, Marlieke de, additional, Durante-Mangoni, Emanuele, additional, Huttner, Angela, additional, Kalil, Andre C., additional, Kaye, Keith, additional, Lee, Todd C., additional, Paterson, David, additional, Gentil, Pilar Retamar, additional, Baño, Jesus Rodríiguez, additional, Scudeller, Luigia, additional, Tacconelli, Evelina, additional, Thwaites, Guy, additional, Tong, Steven, additional, Varon, Ben, additional, and Yahav, Dafna, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results